lung cancer

News

FDA grants fast review for AstraZeneca's Tagrisso in early-s...

The FDA has granted a fast review for AstraZeneca’s Tagrisso oncology drug in certain patients with early-stage lung cancer.

News

Amgen offers hope in KRAS-mutated cancer with sotorasib read...

Last year Amgen intrigued scientists and investors alike after announcing data showing it had produced the first drug that seemed to work against KRAS mutations, which are found in lung and

News

Blueprint and Roche take on Lilly as FDA approves RET-target...

Cancer drugs firm Blueprint Medicines has gained a second US approval, with its Gavreto (pralsetinib) daily pill that targets non-small cell lung cancer with RET fusion mutations.<

News

AZ aims to cut cancer clinic visits with new Imfinzi regimen

The FDA is to review data supporting AstraZeneca’s Imfinzi (durvalumab) cancer immunotherapy in a new four-week regimen that will halve the number of required clinic visits for patients wit

News

AstraZeneca inks $6bn cancer drug deal with Daiichi Sankyo

AstraZeneca has begun a new agreement with Daiichi Sankyo to develop and market an antibody to treat cancer, worth up to $6 billion.

News

ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cance...

With an FDA approval for HER2-positive breast cancer already in the bag, Daiichi Sankyo and AstraZeneca’s Enhertu now looks like it may be able to add lung, stomach and colorec

FDA grants fast review for AstraZeneca's Tagrisso in early-s...

Amgen offers hope in KRAS-mutated cancer with sotorasib read...

Blueprint and Roche take on Lilly as FDA approves RET-target...

AZ aims to cut cancer clinic visits with new Imfinzi regimen

AstraZeneca inks $6bn cancer drug deal with Daiichi Sankyo

ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cance...

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

lung cancer

Editor's Picks